简介：摘要：科学调查和研究发现，包括新型冠状病毒在内的许多病毒，都会通过消化道感染。实行分餐制，有助于阻断病毒经口腔进入消化道的传播途径。此外，还对引导合理膳食，塑造自主自律的健康饮食行为大有裨益。本文通过追溯中国的分餐制历史，分析新冠病毒在消化道传播感染的原因，论述了在国内推行分餐制的优点及可行性，并提出了推行分餐制改革的建议。

简介：

简介：

简介：

简介：摘要 目的：研究新冠疫情对郑州市脑卒中患者症状、干预措施等的影响。方法：以2019年2月至12月和2020年同期至郑州人民医院卒中中心就诊的患者共计1251例为调查对象，根据郑州人民医院卒中中心提取资料，以2019年2月至12月脑卒中患者752例为对照组，2020年同期499例为观察组。结果：疫情期间脑卒中患者就诊总人数相比疫情前脑卒中就诊总人数较同期下降46.5%( 187例vs100例)。其中农村患者较2019年同期减少73.5%(34例vs9例)。其余疫情前较疫情期间脑卒中患者的一般资料比较差异均无统计学意义(P>0.05)。疫情期间进行多模核磁共振检查的人数减少(P

简介：

简介：摘要：2020年COVID-19疫情平息将近两个月后，北京新发地农产品批发市场再次突发疫情。北京市政府及疾控中心充分学习总结防治新冠病毒经验后，处理疫情更加从容有序，不到一个月时间迅速有效控制病毒蔓延。

简介：摘要2019冠状病毒病（COVID-19）在我国暴发以来，目前进入全民防控阶段，其主要传染源是新型冠状病毒肺炎患者，但无症状感染者也可能成为传染源，因孕妇机体处于免疫抑制状态，对呼吸道病原体更易感，易发展为重症。疫情期间，孕产妇仍需要至医院进行必要的产前检查或终止妊娠等产科干预。针对以上特殊性，首都医科大学附属北京佑安医院制定了在疫情之下孕产妇的诊疗流程，调整和优化门诊产检及住院治疗过程，力求把疫情对孕产妇诊疗的影响降到最低，保证母婴健康。同时制定医护人员相关防护流程，有效避免院内感染发生，为疫情期间产科诊疗方案的制定提供参考。

简介：摘要疫苗接种依然是人类历史上对抗不同病毒感染的最有效干预手段。新型冠状病毒(COVID－19)疫苗在预防COVID－19方面的总体益处已得到充分证实。与此同时，也出现了COVID－19疫苗接种后眼部不良反应的报告，可累及眼部多种组织，如眼睑、角膜、巩膜、视网膜、葡萄膜、神经和血管等，临床表现为角膜炎、葡萄膜炎、视网膜炎、神经麻痹、血管阻塞等。眼科医生应关注COVID－19疫苗接种后眼部不良反应的发生。(国际眼科纵览，2022, 46：385－390)

简介：AbstractForecasting the COVID-19 confirmed cases, deaths, and recoveries demands time to know the severity of the novel coronavirus. This research aims to predict all types of COVID-19 cases (verified people, deaths, and recoveries) from the deadliest 3rd wave data of the COVID-19 pandemic in Bangladesh. We used the official website of the Directorate General of Health Services as our data source. To identify and predict the upcoming trends of the COVID-19 situation of Bangladesh, we fit the Auto-Regressive Integrated Moving Average (ARIMA) model on the data from Mar. 01, 2021 to Jul. 31, 2021. The finding of the ARIMA model (forecast model) reveals that infected, deaths, and recoveries number will have experienced exponential growth in Bangladesh to October 2021. Our model reports that confirmed cases and deaths will escalate by four times, and the recoveries will improve by five times at a later point in October 2021 if the trend of the three scenarios of COVID-19 from March to July lasts. The prediction of the COVID-19 scenario for the next three months is very frightening in Bangladesh, so the strategic planner and field-level personnel need to search for suitable policies and strategies and adopt these for controlling the mass transmission of the virus.

简介：

简介：

简介：摘要：目的研究天眼人工智能(Artificial Intelligence,AI) CT在新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)疫情期间的临床应用价值。研究方法是在2021年7月-2021年8月疫情期间，医院使用带有天眼AI技术的CT与普通CT分别对疑似或确诊患有新型冠状病毒肺炎的患者做CT胸部平扫检查的数据统计，进行比较和分析。结果是在临床上应用天眼AI CT的检查次数更多。结论：天眼AICT于COVID-19胸部CT检查，不但实现患者与放射科技师的无接触，降低医护人员及院内感染风险，而且能够提高检查速度，对临床工作起到积极的作用。

简介：AbstractThe impact of coronavirus disease 2019 (COVID-19) on endometriosis (EM) is currently unclear. Here, we aimed to describe the potential influence of COVID-19 on the pathogenesis, clinical symptoms, and treatment of EM. The cytokine storm caused by COVID-19 may induce the occurrence and progression of EM, and immunosuppression of COVID-19 may help the ectopic endometrium escape from immune clearance. Consequently, the forced social isolation and the cancelation of non-emergency medical treatment during the COVID-19 pandemic aggravate anxiety and psychological pressure, which can aggravate the symptoms related to EM and delay routine medical services.

简介：无

简介：无

简介：AbstractBackground:To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods:This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results:A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions:SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Trial registration:Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term= NCT04260594&draw=2&rank=1

简介：摘要由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒疾病（COVID-19）已经在全球多个国家引起大流行，该病毒传染性强、致死率高，部分变异株在病毒传播性、致病性和免疫原性等多方面发生变化。无症状感染和有症状感染的COVID-19患者在免疫特征上存在异质性；不同年龄阶段的COVID-19患者的临床表现也不尽相同。目前无治疗COVID-19的特效药物，疫情控制需依赖新型冠状病毒疫苗的接种，如核酸疫苗、灭活疫苗、病毒载体疫苗、蛋白质疫苗等。本文通过对新型冠状病毒的变异、临床表现、治疗和疫苗等方面文献的复习，展现目前相关研究的进展。

简介：摘要Coronavirus disease (COVID-19), the infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported on December 31, 2019. Because it has only been studied for just over three months, our understanding of this disease is still incomplete, particularly regarding its sequelae and long-term outcomes. Moreover, very little has been written about the rehabilitation needs of patients with COVID-19 after discharge from acute care. The objective of this report is to answer the question " What rehabilitation services do survivors of COVID-19 require？" The question was asked within the context of a subacute hospital delivering geriatric inpatient and outpatient rehabilitation services. Three areas relevant to rehabilitation after COVID-19 were identified. First, details of how patients may present have been summarized, including comorbidities, complications from an intensive care unit stay with or without intubation, and the effects of the virus on multiple body systems, including those pertaining to cardiac, neurological, cognitive, and mental health. Second, I have suggested procedures regarding the design of inpatient rehabilitation units for COVID-19 survivors, staffing issues, and considerations for outpatient rehabilitation. Third, guidelines for rehabilitation (physiotherapy, occupational therapy, speech-language pathology) following COVID-19 have been proposed with respect to recovery of the respiratory system as well as recovery of mobility and function. A thorough assessment and an individualized, progressive treatment plan which focuses on function, disability, and return to participation in society will help each patient to maximize their function and quality of life. Careful consideration of the rehabilitation environment will ensure that all patients recover as completely as possible.

简介：AbstractCoronavirus disease 2019 (COVID-19) is a newly emerged infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The number of COVID-19 cases is continuously increasing and no effective drugs or vaccines are currently available. Accurate and efficient diagnostic testing methods are desperately needed for the detection of SARS-CoV-2 and antiviral antibodies in infected individuals. Various assay techniques, including nucleic acid tests [eg, polymerase chain reaction (PCR), reverse transcription-PCR, real-time loop-mediated isothermal amplification, and CRISPR-Cas-based detection], serological tests [eg, immunoglobulin (Ig)A, IgM/G], imaging tests (eg, computed tomography and positron-emission tomography), and nanoparticle-based detections have been reported for COVID-19 diagnosis. This review aims to present the current diagnostic tools for SARS-CoV-2 and their performance characteristics to inform the appropriate selection of diagnostic and surveillance technologies at optimal testing times. We also describe the advantages of detection using combined nucleic acid and imaging tests, or serological testing and point-of-care diagnostics. Developing reliable protein biomarkers targeting the conserved proteins of SARS-CoV-2 rather than IgA, IgM, or IgG would be useful to manage SARS-CoV-2.